A detailed history of Handelsbanken Fonder Ab transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 17,667 shares of ASND stock, worth $2.37 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
17,667
Previous 13,467 31.19%
Holding current value
$2.37 Million
Previous $1.84 Million 43.6%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$113.0 - $153.43 $474,600 - $644,406
4,200 Added 31.19%
17,667 $2.64 Million
Q2 2024

Aug 05, 2024

BUY
$121.07 - $153.67 $145,284 - $184,403
1,200 Added 9.78%
13,467 $1.84 Million
Q1 2024

May 13, 2024

BUY
$123.45 - $159.4 $111,105 - $143,460
900 Added 7.92%
12,267 $1.85 Million
Q3 2023

Oct 19, 2023

BUY
$86.5 - $103.97 $204,745 - $246,096
2,367 Added 26.3%
11,367 $1.06 Million
Q2 2023

Aug 02, 2023

BUY
$69.96 - $97.84 $34,980 - $48,920
500 Added 5.88%
9,000 $803,000
Q1 2023

Apr 28, 2023

BUY
$104.9 - $126.78 $146,860 - $177,492
1,400 Added 19.72%
8,500 $911,000
Q4 2022

Feb 07, 2023

SELL
$99.42 - $131.97 $248,550 - $329,925
-2,500 Reduced 26.04%
7,100 $867,000
Q2 2022

Aug 03, 2022

SELL
$78.08 - $117.61 $7,808 - $11,761
-100 Reduced 1.03%
9,600 $892,000
Q4 2021

Feb 08, 2022

SELL
$127.1 - $169.66 $114,390 - $152,694
-900 Reduced 8.49%
9,700 $1.31 Million
Q3 2021

Nov 10, 2021

BUY
$112.67 - $176.92 $146,471 - $229,995
1,300 Added 13.98%
10,600 $1.69 Million
Q1 2021

Apr 29, 2021

SELL
$124.92 - $173.33 $124,920 - $173,330
-1,000 Reduced 9.71%
9,300 $1.2 Million
Q4 2020

Feb 11, 2021

BUY
$151.2 - $182.76 $241,919 - $292,416
1,600 Added 18.39%
10,300 $1.72 Million
Q2 2020

Aug 13, 2020

BUY
$110.87 - $156.01 $964,569 - $1.36 Million
8,700 New
8,700 $1.29 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.49B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.